Qiming Medical receives approval for China's first second-generation prosthetic valve system

On November 16th Qiming Medical announced that its self-developed VenusA-Plus artificial aortic valve replacement system, the recyclable delivery system, had been approved for listing by the State Drug Administration.
VenusA-Plus is China's first approved recyclable catheter aortic valve replacement system, adding recyclable, repositionable functionality to its advantages of retaining the strong radial support of the first generation OfusA-Valve valve system.
of Veneus A-Plus marks the beginning of a "recyclable era" for China's original artificial valve system.
chinese aortic valve stenosis patients have a high proportion of dile leaf valve malformations, such patients usually show the characteristics of calcified weight, asymmetry, combined aortic disease, etc. , the operation is more difficult.
VenusA-Plus optimizes surgical operation, improves surgical success rate and safety, and is expected to significantly accelerate the promotion and technology of catheterized artificial aortic valve replacement ("TAVR") in China.
VenusA-Plus Registered Clinical Trials were conducted by Professor Wang Jian'an of the Second Hospital affiliated with Zhejiang University School of Medicine, with the participation of Sun Yat-sen Hospital affiliated with Fudan University, Yan foreign hospital of the Chinese Academy of Medical Sciences and Huaxi Hospital of Sichuan University.
Compared to The Venus A-Valve valve system, the Venus A-Plus valve system shows better safety, with a compound endpoint event rate lower than the pre-set target boundary, demonstrating the product's good clinical safety, effectiveness and handling.